Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 20/20 | 0.54 |
| ▸ | TDO2 | P48775 | 8/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.54 |
| ▸ | CYP2C8 | P10632 | 3/20 | 0.54 |
| ▸ | CHRNA1 | P02708 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21034705 | 0.86 | IDO1 (0.49) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21061197 | 0.82 | IDO1 (0.64) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21061127 | 0.81 | IDO1 (0.69) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL17742785 | 0.79 | IDO1 (0.54) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL17729192 | 0.79 | IDO1 (0.54) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21949771 | 0.79 | IDO1 (0.54) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21265979 | 0.78 | IDO1 (0.56) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL17730175 | 0.77 | IDO1 (0.59) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL21138828 | 0.77 | IDO1 (0.61) | IDO1TDO2CYP2C9CYP2C8CHRNA1 | |
| SCHEMBL20620323 | 0.77 | IDO1 (0.56) | IDO1TDO2CYP2C9CYP2C8CHRNA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | BEIGENE, LTD. (KY) | 2022-10-18 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | BEONE MEDICINES I GMBH (CH) | 2020-10-08 | — | — | US | disclosed |
| CN-111386114-A | Novel benzimidazoles as selective inhibitors of indoleamine 2, 3-dioxygenase | 百济神州有限公司 | 2020-07-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317638-A1 | NOVEL BENZOIMIDAZOLES AS SELECTIVE INHIBITORS OF INDOLEAMINE 2,3-DIOXYGENASES | IDO2, IDO1, TPH2 | IDO1 2/4885TDO2 6/4885CYP2C9 304/4885 |
| US-11472788-B2 | Benzoimidazoles as selective inhibitors of indoleamine 2,3-dioxygenases | IDO1, IDO2, TPH2 | IDO1 1/4885TDO2 5/4885CYP2C9 180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.